CARA vs. COYA, IGMS, ABOS, HLVX, VOR, MNOV, PYXS, PWUP, DBVT, and VIGL
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Coya Therapeutics (COYA), IGM Biosciences (IGMS), Acumen Pharmaceuticals (ABOS), HilleVax (HLVX), Vor Biopharma (VOR), MediciNova (MNOV), Pyxis Oncology (PYXS), PowerUp Acquisition (PWUP), DBV Technologies (DBVT), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry.
Cara Therapeutics vs.
Cara Therapeutics (NASDAQ:CARA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.
Cara Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
In the previous week, Cara Therapeutics had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Cara Therapeutics and 3 mentions for Coya Therapeutics. Cara Therapeutics' average media sentiment score of 0.72 beat Coya Therapeutics' score of 0.40 indicating that Cara Therapeutics is being referred to more favorably in the media.
Cara Therapeutics received 650 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 94.44% of users gave Coya Therapeutics an outperform vote while only 72.50% of users gave Cara Therapeutics an outperform vote.
44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Coya Therapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Coya Therapeutics' return on equity of -31.63% beat Cara Therapeutics' return on equity.
Cara Therapeutics presently has a consensus target price of $27.84, suggesting a potential upside of 475.21%. Coya Therapeutics has a consensus target price of $16.25, suggesting a potential upside of 167.27%. Given Cara Therapeutics' higher probable upside, research analysts clearly believe Cara Therapeutics is more favorable than Coya Therapeutics.
Coya Therapeutics has lower revenue, but higher earnings than Cara Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Coya Therapeutics beats Cara Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CARA) was last updated on 2/1/2025 by MarketBeat.com Staff
